SYSTEMATIC REVIEW WITH META-ANALYSIS: SAFETY AND EFFICTIVENESS OF COMBINING BIOLOGICS AND SMALL MOLECULES IN INFLMAMMATORY BOWEL DISEASE

Ali Osman,Scott Anderson,Mohammad Zamani,Quazim Alayo,Bruce Sands,Jean-Francois Rahier,Jean-Frederic Colombel,Parakkal Deepak
DOI: https://doi.org/10.1093/ibd/izae020.193
2024-01-25
Inflammatory Bowel Diseases
Abstract:Abstract BACKGROUND Effectiveness and safety of Dual biologic therapy (DBT) or in combination with small molecules for treatment of refractory cases of inflammatory bowel diseases (IBD) has been studied previously. In this systematic review and meta-analysis (SRMA), our aim was to update prior SRMA by Alayo et al including newer studies and randomized clinical trials Explorer and VEGA and newer endpoints including corticosteroid free remission rates, need for surgeries, and effectiveness based on IBD subtype. METHODS We conducted a systematic literature search using Clinical trials.gov, Cochrane Library, Embase, Ovid Medline, PubMed Medline, Scopus and Web of Science, identifying additional relevant studies published until January 19, 2023. Random-effects inverse variance model was used to combine the proportions of patients who achieved response/remission or developed AEs to obtain pooled estimates (primary outcomes). RESULTS A total of 1184 citations were identified through the database searches, of which 360 duplicates and 755 unsuitable studies were excluded following title/abstract screening. Then, the full-texts of the remaining 69 articles were retrieved for further investigation. Of these, 59 were excluded, leaving 10 additional eligible studies since the prior systematic review. A total of 23 studies met the inclusion criteria including 13 in prior SRMA, published between 2007 and 2023. Final analysis included 531 patients who underwent 543 therapeutic trials (TTs) of 8 different combination therapies. Of these 264 (49.7%) were men men. Among combination therapies, Ustekinumab (UST) + anti-tumor necrosis factor-alpha antagonist (aTNF) had the highest pooled clinical response (81.6% [95% CI: 66.2-97.0], I2=52%, p=0.04; 9 studies, 44 TTs) and remission (Figure 1) (64.2% [95% CI: 45.2-83.1], I2=55%, p=0.03; 8 studies, 42 TTs) rates. In patients with CD, the highest pooled clinical response and remission rates pertained to UST + aTNF (91.6% [95% CI: 79.8-100.0], I2 = 19%, p=0.28; 8 studies, 29 TTs). In patients with UC, the highest pooled clinical response rate was seen with Vedolizumab (VDZ)+UST (100.0% [95% CI: 70.0-100.0], I2 = 0%, p=1.00; 4 studies, 4 TTs) and UST + aTNF (100.0% [95% CI: 73.2-100.0], I2 = 0%, p =1.00; 4 studies, 5 TTs). and while the highest pooled clinical remission rate was with VDZ + UST (75.0% [95% CI: 26.0-100.0], I2 = 63%, p=0.05; 4 studies, 4 TTs). The lowest pooled AEs rate (Figure 2) related to tofacitinib (Tofa) + VDZ (12.5% [95% CI: 2.9-22.0], I2 = 41%, p = 0.10; 8 studies, 76 TTs), followed by UST + aTNF (12.7% [95% CI: 0.0-25.8], I2=43%, p = 0.08; 9 studies, 43 TTs) and Tofa+aTNF (13.0% [95% CI: 0.8-25.3], I2=49%, p=0.08; 6 studies, 27 TTs) in patients with IBD. CONCLUSION Combining biologics or with small molecules in treatment of refractory IBD is promising and appeared to be generally safe with no major side effects. Figure 1 Clinical remission Figure 2 Adverse events
gastroenterology & hepatology
What problem does this paper attempt to address?
Based on the provided text content, this research paper mainly explores the safety and efficacy of the combined use of biologics and small - molecule drugs in the treatment of refractory Inflammatory Bowel Disease (IBD). Specifically, the study aims to update the previous Systematic Review and Meta - Analysis (SRMA) conducted by Alayo et al. by including new studies and randomized controlled trials (such as the Explorer and VEGA trials), as well as new endpoint indicators (such as steroid - free remission rate, surgical need, and efficacy assessment based on IBD subtypes) to more comprehensively evaluate the effects of these combination therapies. ### Research Background - **Objective**: To evaluate the safety and efficacy of the combined use of biologics or in combination with small - molecule drugs in the treatment of refractory IBD. - **Methods**: A systematic literature search was conducted using multiple databases (such as ClinicalTrials.gov, Cochrane Library, Embase, Ovid Medline, PubMed Medline, Scopus, and Web of Science) to identify relevant studies as of January 19, 2023. A random - effects inverse - variance model combined with the proportion of patients achieving response/remission or experiencing adverse events (AEs) was used to obtain pooled estimates (primary results). ### Main Findings - **Overall Results**: The final analysis included 531 patients, with a total of 543 Therapeutic Trials (TTs) involving 8 different combination therapies. - **Best Response Rate**: - For Crohn's Disease (CD), Ustekinumab (UST) + anti - Tumor Necrosis Factor α antagonist (aTNF) had the highest clinical response rate (91.6%, 95% CI: 79.8 - 100.0, I² = 19%, p = 0.28; 8 studies, 29 TTs). - For Ulcerative Colitis (UC), Vedolizumab (VDZ) + UST had the highest clinical response rate (100.0%, 95% CI: 70.0 - 100.0, I² = 0%, p = 1.00; 4 studies, 4 TTs). - **Lowest Adverse Event Rate**: Tofacitinib (Tofa) + VDZ had the lowest adverse event rate (12.5%, 95% CI: 2.9 - 22.0, I² = 41%, p = 0.10; 8 studies, 76 TTs). ### Conclusions - **Safety and Efficacy**: The combined use of biologics or with small - molecule drugs shows promise in the treatment of refractory IBD and is generally considered safe without major side effects. ### Formulas - **Confidence Interval**: [95% CI] - **Heterogeneity Statistic**: [I²] This paper provides important evidence support for the treatment of refractory IBD through systematic review and meta - analysis, especially for those patients who respond poorly to single - agent therapy.